SCHEMBL14825801

SCHEMBL14825801

CCOC(=O)c1cccc(CN2CCC(=C3c4ccccc4CCc4ccccc43)CC2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH1 P35367 3/20 0.49
▸ CYP1A2 P05177 1/20 0.46
▸ PTAFR P25105 2/20 0.46
▸ KMT2A Q03164 2/20 0.43
▸ SETD7 Q8WTS6 1/20 0.42
▸ MAPT P10636 2/20 0.42
▸ FNTA P49354 2/20 0.41
▸ FNTB P49356 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ HPGD P15428 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ SLC6A15 Q9H2J7 2/20 0.41
▸ GABRP O00591 1/20 0.40
▸ GABRD O14764 1/20 0.40
▸ GABRA1 P14867 1/20 0.40
▸ GABRB1 P18505 1/20 0.40
▸ GABRG2 P18507 1/20 0.40
▸ GABRB3 P28472 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14825810 0.90 KCNH2 (0.45) HRH1CYP1A2PTAFRKMT2ASETD7
SCHEMBL14814023 0.85 PTAFR (0.48) HRH1PTAFRKMT2ASETD7MAPT
SCHEMBL14825564 0.85 SLC6A15 (0.46) HRH1KMT2AMAPTFNTAFNTB
SCHEMBL14825552 0.85 KCNH2 (0.51) HRH1CYP1A2PTAFRKMT2AMAPT
SCHEMBL14827215 0.80 HRH1 (0.52) HRH1PTAFRKMT2ASETD7MAPT
SCHEMBL14825808 0.79 CYP1A2 (0.45) CYP1A2MAPTFNTAFNTBKDM4E
SCHEMBL14825792 0.78 SETD7 (0.50) HRH1CYP1A2PTAFRKMT2ASETD7
SCHEMBL14825804 0.76 KDM4E (0.52) HRH1PTAFRKMT2ASETD7MAPT
SCHEMBL2822250 0.76 CYP1A2 (0.55) CYP1A2MAPTKDM4EALDH1A1BCHE
SCHEMBL2817557 0.76 CYP1A2 (0.55) CYP1A2KMT2AMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 — — US disclosed
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 — — US disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 — — US disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST HRH2, HRH4, HRH1 HRH1 3/4885CYP1A2 494/4885PTAFR 2062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback